Shattuck Labs Announces Participation in Upcoming November Investor Conferences
November 03, 2021 17:19 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Changes to its Board of Directors
October 28, 2021 16:30 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 01, 2021 09:56 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Upcoming September Conferences
September 01, 2021 16:30 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252
August 11, 2021 16:30 ET
|
Shattuck Labs, Inc.
– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for...
Shattuck Labs Announces Participation in the BTIG Biotechnology Conference
August 06, 2021 10:40 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021
August 04, 2021 08:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer
June 01, 2021 10:44 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 10, 2021 07:00 ET
|
Shattuck Labs, Inc.
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – IND filings for...
Shattuck Labs Announces Participation in Upcoming May Conferences
April 30, 2021 17:33 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...